plumbagin has been researched along with Cell Transformation, Neoplastic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, R; Cao, Y; Couch, FJ; Dutta, S; Elkhanany, A; Iyer, S; Mondal, G; Mukhopadhyay, D; Pal, K; Shridhar, V; Sinha, S; Somasundaram, V; Srinivas, P | 1 |
1 other study(ies) available for plumbagin and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; BRCA2 Protein; Calcium; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cisplatin; Endothelial Cells; Female; Glucose Transporter Type 1; Humans; Ki-67 Antigen; Mice; Mice, SCID; Naphthoquinones; Neovascularization, Pathologic; Ovarian Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |